A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers. The findings, published in Urologic Oncology: Seminars and Original Investigations, suggest that factors such as race, socioeconomic status, and the type of healthcare facility influence whether patients will receive these effective therapies.
Although the use of immunotherapies for these advanced cancers increased throughout the study period, persistent disparities remained.
